Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

It plans to estimate the "comparative therapeutic impact" of the two drugs compared to their respective fixed-dose generic alternatives or open generic combinations in patients with moderate to ...

As the EU patent expires on its flagship respiratory ... though the drug lags behind its rivals, Bayer/J&J's Xarelto and Pfizer/BMS's Eliquis, in market share terms. Meanwhile diabetes treatmeant ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

The researchers examined expected patient costs for preferred brand name drugs often lacking generic equivalents ... from $54.04 to $128.43 Xarelto (rivaroxaban) for blood clots, from $46.54 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Beyonttra's launch is one of Bayer's “must-win battles” as the German company navigates the loss of exclusivity of its top-selling drug, blood thinner Xarelto, Stefan Oelrich, head of Bayer ...